GSK3B and cholangiocarcinoma: They not only facilitate rapid dephosphorylation of GSK-3β, leading to β-catenin degradation in CCA cells but also inhibit 15-hydroxyprostaglandin dehydrogenase (15-PGDH) expression induced by COX-2, thus delaying malignant progression [110].